Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 9:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Triglycerides High Clear all
Completed Phase 2 Interventional Results available

Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists

NCT06640972
View directory record Official record
Conditions
Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
Interventions
RDX-002, Placebo
Drug
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Metformin on Blood Vessel Structure and Function

NCT00105066
View directory record Official record
Conditions
Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions
Metformin, Placebo
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal

NCT02894112
View directory record Official record
Conditions
Oral Glucose Tolerance Test, High Fat Tolerance Test
Interventions
non-fat milk, carbohydrate control beverage, caloric control beverage
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
20 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

The Impact of Omega Three Fatty Acids on Vascular Function in HIV

NCT01041521
View directory record Official record
Conditions
High Triglyceride Level, HIV Infection
Interventions
Lovaza
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

NCT00903409
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin + Lovaza® (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • Encinitas, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Not applicable Interventional

Effect of a Grape Seed Extract (GSE) on Insulin Resistance

NCT01889368
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Grape Seed Extract, Placebo
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mather, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

NCT00812955
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
ABT-143, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
129
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

NCT01262638
View directory record Official record
Conditions
Dyslipidemia
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
11
States / cities
Chandler, Arizona • Greenbrae, California • Santa Rosa, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 14, 2026, 9:20 AM EDT
Recruiting Phase 2 Interventional

A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol

NCT07199309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
MAR001, Placebo
Drug
Lead sponsor
Marea Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fructose-Induced Palmitate Synthesis in Overweight Subjects

NCT00535535
View directory record Official record
Conditions
Elevated Triglycerides, Diabetes, Cardiovascular Disease
Interventions
Fructose, Fructose and Glucose
Dietary Supplement
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2013 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Not applicable Interventional

The Effect of Avocado on Cardiovascular Disease (CVD) Risk Factors

NCT01235832
View directory record Official record
Conditions
Cardiovascular Disease, Hyperlipidemia
Interventions
Avocado Diet, Lower-Fat Diet, Moderate Fat Diet
Other
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Aged 20-60 Years Old

NCT01797042
View directory record Official record
Conditions
Obesity
Interventions
Dietary Compliance
Behavioral
Lead sponsor
Rippe Lifestyle Institute
Industry
Eligibility
20 Years to 60 Years
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Celebration, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Sep 14, 2026, 9:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Docosapentaenoic Acid on Lipids and Other Risk Factors for Cardiovascular Disease

NCT04088240
View directory record Official record
Conditions
Elevated Triglycerides, Cardiovascular Risk Factor
Interventions
DPA enriched n-3, n-3 control, Placebo
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 14, 2026, 9:20 AM EDT
Withdrawn Not applicable Interventional

Effects of Mixed Exercise Regime and L-Carnitine Supplementation in HIV Patients on HAART

NCT00572429
View directory record Official record
Conditions
HIV Infections, Hyperlipidemia, Exercise
Interventions
l-carnitine
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 14, 2026, 9:20 AM EDT
Recruiting Not applicable Interventional

Pilot Study of "Bottarga" Supplementation: A Little-known, Sustainable "Blue" Food

NCT06988462
View directory record Official record
Conditions
Prediabetes, Diabetes, High Cholesterol/Hyperlipidemia, Obesity & Overweight, Triglycerides, HDL Cholesterol
Interventions
Bottarga, Comparator
Other
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sommerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 2 Interventional

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

NCT05889156
View directory record Official record
Conditions
High Triglycerides
Interventions
NST-1024, Placebo
Drug · Other
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
18 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 3 Interventional

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

NCT03398005
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
CaPre, Placebo
Drug
Lead sponsor
Grace Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

NCT01879319
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab AMD, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
22
States / cities
Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Not applicable Interventional Results available

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

NCT00504309
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
4/day of 4g P-OM3 capsules, 4/day of 1g P-OM3 capsules, Corn Oil Placebo, 4 capsules/day for 8 weeks
Drug
Lead sponsor
Penn State University
Other
Eligibility
21 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

NCT00891293
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
32
States / cities
Spring Valley, California • Washington D.C., District of Columbia • Coral Gables, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 4 Interventional Results available

Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy

NCT02926027
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Vascepa, placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Torrance, California • Murray, Utah
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

NCT00728338
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Docosahexenoic acid (DHA), Olive oil
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
39 Years to 66 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Sep 14, 2026, 9:20 AM EDT
Completed Phase 3 Interventional

A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides

NCT00134498
View directory record Official record
Conditions
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Interventions
torcetrapib/atorvastatin, atorvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
39
States / cities
Anaheim, California • Huntington Beach, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2007 · Synced Sep 14, 2026, 9:20 AM EDT